论文部分内容阅读
目的:分析SDF-1在乳腺癌患者外周血中的表达水平,探讨其临床意义。方法:Elisa法检测乳腺癌患者术前及术后血清SDF-1水平,分析其与乳腺癌临床病理特征的关系。结果:乳腺癌患者术前(69例)血清SDF-1水平明显高于正常对照组(20例)(6406.7±1302.5 pg/m L vs 5217.4±1225.7 pg/m L),有明显统计学差异(P<0.01),发生远处转移的乳腺癌患者(11例)血清SDF-1水平明显高于未发生转移者(58例)(7656.4±784.1 pg/m L vs 6169.7±1364.6 pg/m L),差异具有明显统计学意义(P<0.01)。ER及Her-2表达阳性乳腺癌的患者SDF-1水平较ER及Her-2表达阴性者低,差异亦有统计学意义(P<0.05)。结论:SDF-1可能是预测乳腺癌发生及远处转移的重要标志物。
Objective: To analyze the expression of SDF-1 in peripheral blood of breast cancer patients and to explore its clinical significance. Methods: The serum and serum levels of SDF-1 in breast cancer patients before and after operation were detected by Elisa method and their relationship with the clinicopathological features of breast cancer were analyzed. Results: The serum levels of SDF-1 in preoperative breast cancer patients (69 cases) were significantly higher than those in normal controls (20 cases) (6406.7 ± 1302.5 pg / m L vs 5217.4 ± 1225.7 pg / m L) (P <0.01). The serum levels of SDF-1 in patients with distant metastasis (11 cases) were significantly higher than those without metastasis (58 cases) (7656.4 ± 784.1 pg / m L vs 6169.7 ± 1364.6 pg / m L) , The difference was statistically significant (P <0.01). The level of SDF-1 in ER and Her-2 positive breast cancer patients was lower than that in ER and Her-2 negative patients (P <0.05). Conclusion: SDF-1 may be an important marker of breast cancer occurrence and distant metastasis.